Amplification or mutations of FGFR-1 have been reported in breast cancer (10%) [94], lung adenocarcinoma (21%) [95], oral squamous cell carcinoma (17.4%) [96], and GBM [97], whereas FGFR-2 amplification or mutations have been reported in about 2% breast cancer [98], 10% gastric cancer [99], 12% endometrial cancer [100], and lung cancer [98]. This evidence concerns the gene FGFR2 and breast cancer.